Pharmaceutical News
-
Lilly Launches Zepbound Multi-Dose KwikPen for Monthly Obesity Treatment Nationwide
Eli Lilly and Company has launched a multi-dose KwikPen® for Zepbound® (tirzepatide), offering four weekly doses in one device for ease of administration. Priced at $299 for eligible self-pay patients, the pen aims to enhance access to this leading obesity treatment, which has shown significant weight loss effects in clinical trials. Read more
-
MoonLake’s Sonelokimab Shows Clinically Meaningful Benefit in Phase 2 axSpA Trial
MoonLake Immunotherapeutics reported promising results from its Phase 2 S-OLARIS trial of sonelokimab (SLK) for axial spondyloarthritis, with 81% of 26 patients achieving significant improvement at Week 12. The trial noted reduced inflammation via imaging and a favorable safety profile, indicating SLK’s potential for disease modification without new safety concerns. Read more
-
The Unstoppable Trump! Moves Swiftly With 10% Global Tariff After Supreme Court Blocks Emergency Duties
Following the Supreme Court’s February 2026 ruling limiting presidential tariff powers, former President Trump announced a temporary 10% global tariff using Section 122 of the Trade Act. Analysts suggest this move aims to maintain trade pressure, indicating a strategic legal shift rather than an abandonment of protectionist policies. Read more
-
FDA Accepts Teva’s NDA for Once-Monthly Olanzapine Injectable for Schizophrenia
Teva Pharmaceuticals’ New Drug Application (NDA) for olanzapine extended-release injectable suspension (TEV-749) has been accepted by the FDA. This once-monthly treatment for schizophrenia, supported by the Phase 3 SOLARIS trial, may enhance adherence and stability. If approved, it could significantly improve treatment outcomes for patients. Read more
-
WHO Confirms Libya Eliminates Trachoma as Public Health Problem in 2026
The WHO announced Libya’s successful elimination of trachoma as a public health issue, marking a significant milestone for the nation and the Eastern Mediterranean Region. This achievement protects future generations from blindness and highlights effective interventions against neglected tropical diseases. Libya is now the 28th country globally to achieve this status. Read more
-
FDA Approves BYSANTI for Bipolar I Disorder and Schizophrenia Treatment
Vanda Pharmaceuticals Inc. announced FDA approval for BYSANTI™ (milsaperidone) tablets as a first-line treatment for manic episodes in bipolar I disorder and schizophrenia in adults. This atypical antipsychotic shows bioequivalence to iloperidone and will be commercially available by Q3 2026, with ongoing studies for treatment-resistant depression. Read more
-
Moderna to Present at TD Cowen and Barclays 2026 Conferences
Moderna, Inc. will participate in two investor conferences in March 2026, presenting at the TD Cowen Healthcare Conference on March 3 at 1:50 p.m. ET and the Barclays Global Healthcare Conference on March 10 at 9:30 a.m. ET. Live webcasts will be available on its website, with replays for 30 days. Read more
-
Novartis to Present Expanded Rhapsido (remibrutinib) Data at AAAAI 2026
Novartis will present new data on remibrutinib at the AAAAI Annual Meeting in February 2026. The research from the Phase III REMIX trials highlights its effectiveness in chronic spontaneous urticaria and initial data in peanut allergy. Plans for a Phase III food allergy program are also underway, indicating its broader therapeutic potential. Read more
-
Supreme Court Strikes Down Trump’s Global Tariffs, Easing Some Trade Pressures — Mixed Signals for Pharma Sector
The U.S. Supreme Court ruled 6-3 that former President Trump’s tariffs under the IEEPA were unauthorized, affirming Congress’s tariff authority. This decision impacts U.S. trade policy and the pharmaceutical industry, allowing some relief from previous tariffs, yet leaves uncertainty due to alternative trade statutes. Ongoing legal costs and negotiations may continue to affect global trade. Read more
-
Can Repurposed Medicines and Vaccines Change the Course of Alzheimer’s Disease?
Researchers are exploring repurposed medicines for Alzheimer’s disease (AD) as cases rise globally. A Delphi consensus identified three priority candidates: the herpes zoster vaccine (Zostavax), sildenafil, and riluzole, based on mechanistic plausibility and safety for older adults. Drug repurposing could offer faster, more accessible treatment options for AD. Read more
-
FDA Approves First All-Oral Fixed-Duration VENCLEXTA Combination for Untreated CLL Patients
The FDA has approved VENCLEXTA® (venetoclax) with acalabrutinib for untreated adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This marks the first all-oral treatment regimen, offering significant improvements in progression-free survival compared to traditional chemoimmunotherapy, with potential for time off treatment. Read more
-
Grail Shares Plunge After Large NHS-Galleri Cancer Screening Trial Misses Primary Goal
Shares of Grail, Inc. plummeted nearly 50% after its NHS-Galleri trial failed to significantly reduce late-stage cancer diagnoses. Although a positive trend was noted, results did not meet the primary endpoint. Analysts maintain that FDA approval for the Galleri test remains possible, despite potential scrutiny from Medicare regulators. Read more